Phaseline

Companies › Biotechnology Institute IMASD

Biotechnology Institute IMASD: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 4; Metabolic and endocrine, Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Plasma Rich in Growth Factors (PRGF)
Growth factor-enriched autologous plasma injection
–Phase 4Diseases [C] - Musculoskeletal Diseases [C05; Foot Ulcers, DiabeticFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06715085Plasma Rich in Growth Factors (PRGF)Phase 4Diseases [C] - Musculoskeletal Diseases [C05OtherFeb 2027
NCT06952998Plasma Rich in Growth Factors (PRGF)Phase 4Foot Ulcers, DiabeticMetabolic and endocrineMay 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Soleno Therapeutics Energenesis Biomedical BrightGene Bio-Medical Technology Fresenius Kabi Huons Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.